Introduction {#sec1}
============

BioBank Japan (BBJ) was established with the cooperation of 12 medical institutes, consisting of over 60 hospitals, as a leading project of the Ministry of Education, Culture, Sports, Science and Technology in 2003.[@bib1], [@bib2] As a disease-oriented biobank, BBJ collected DNA and serum samples from approximately 200,000 patients with 47 diseases. BBJ annually updates clinical information, which is another essential element of biobanks.[@bib3] The clinical information associated with the biospecimens was utilized in previous studies to select or stratify the participant group. Samples and their clinical information were used for over 200 studies.[@bib4] However, so far, a comprehensive analysis of the clinical information of the BBJ cohorts has not been conducted. Here, we analyzed clinical information including age, sex, body mass index (BMI), hypertension, smoking, and drinking status across 47 diseases, and compared the results with the Japanese database. In addition, we assessed the association between target diseases and positive family history.

Materials and methods {#sec2}
=====================

Study design {#sec2.1}
------------

In the present cohort, we focused on 47 common diseases ([Table 1](#tbl1){ref-type="table"}). Patients diagnosed with any one of the 47 diseases were recruited from 66 hospitals affiliated with 12 medical institutes between fiscal year of 2003 and 2007. The detailed protocol of the recruitment process has been described elsewhere.[@bib2] Written informed consent was obtained from all participants. The study protocol was reviewed and approved by the Ethics Committees of all participating institutions, including the Institute of Medical Science, the University of Tokyo, and the Center for Integrative Medical Sciences, RIKEN.

We included patients who had been diagnosed with the diseases by physicians at the cooperating hospitals ([eTable 1](#appsec2){ref-type="sec"}). As this project registered not only patients with newly developed diseases but also patients who were diagnosed and treated before starting the project, some participants were enrolled several years after disease onset or diagnosis.[@bib2] We excluded patients who had received a bone marrow transplant and those who were not of East Asian descent.

Clinical information {#sec2.2}
--------------------

Clinical information including common clinical variables, disease-specific variables, prescriptions, and drug side-effect information, was collected from each participant. The detailed methods of the collection of clinical information has been described elsewhere.[@bib2] The clinical database was updated every year until 2012. After a thorough review and data-cleansing of clinical variables,[@bib2] clinical information of 199,982 participants with 47 diseases at enrollment was established on March 31 2015 and used in the current study.

Japanese database {#sec2.3}
-----------------

The Ministry of Health, Labour and Welfare in Japan conducts a Patient Survey every three years and a National Health and Nutrition Survey every year. We obtained the results of the Patient Survey of 2005[@bib5] and those of the National Health and Nutrition Survey of 2006.[@bib6] Table 65 in the Patient Survey was used to estimate Japanese patient numbers, stratified by sex and age for each disease. Distributions of BMI categories, hypertension prevalence, smoking history, and alcohol intake history in the general Japanese population were calculated from Tables 23, 49-2, 97, and 91 of the National Health and Nutrition Survey, respectively.

Analysis of clinical information {#sec2.4}
--------------------------------

The distributions of BMI, hypertension prevalence, smoking history, and alcohol intake history in the BBJ cohort were adjusted for sex and age group for each table in the national public survey when we compared the distributions among the 47 diseases and Japanese database. BMI category and hypertension were defined according to World Health Organization (WHO) criteria as follows: BMI \< 18.5 was defined as underweight, 18.5 ≤ BMI \< 25 as normal, 25 ≤ BMI \< 30 as overweight, and 30 ≤ BMI as obese[@bib7]; hypertension was defined as systolic blood pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg or when participants were prescribed antihypertensive drugs. Multivariate logistic regression analyses were performed to assess the association between each target disease and positive family history associated with the target disease, adjusted for sex and age. SAS 9.4 software was used for the data analysis. A *p*-value of \<0.05 was considered statistically significant.

Results {#sec3}
=======

Basic characteristics (Age and sex) {#sec3.1}
-----------------------------------

We characterized the BioBank Japan cohort at enrollment by analyzing common clinical variables of age and sex across the target diseases. Mean age at enrollment, across the entire cohort or for each disease, was comparable between both sexes, but varied among the diseases ([Table 1](#tbl1){ref-type="table"}). The highest mean age was observed in men with prostate cancer and in women with osteoporosis (72.60 and 73.77 years, respectively), while the youngest mean age was observed in men and women with febrile seizures (4.16 and 4.35 years, respectively), reflecting the typical age of onset of each disease. A greater number of men were registered in the BBJ cohort compared to women (53.05% vs. 46.95%), while sex ratios varied according to the diseases ([Table 1](#tbl1){ref-type="table"}).

To highlight sex and age characteristics of the BBJ cohort, we further compared the sex and age distribution for each disease with the Patient Survey. We included participants with 42 out of the 47 diseases for the comparison, as we obtained the relevant clinical data from the Patient Survey ([eTable 2](#appsec2){ref-type="sec"}). Almost all diseases displayed equivalent age distributions, while lower proportions of participants \<20 years of age were observed in three diseases (bronchial asthma, atopic dermatitis and hay fever), which are likely to occur in younger populations ([eFigs. 1.1--1.5 and eTable 3](#appsec2){ref-type="sec"}). The proportion of male participants with dyslipidemia was considerably higher in the BBJ cohort (50.76%) than in the Patient Survey (33.55%), although both age distributions appeared equivalent. The low proportion of female patients with heart failure aged ≥80 years resulted in a lower proportion of female participants in the BBJ cohort. We also observed a low proportion of elderly female participants with cerebral infarction, chronic obstructive pulmonary disease (COPD), peripheral arterial diseases (PAD), unstable angina, stable angina, and myocardial infarction in the BBJ cohort. Varied distributions between the BBJ cohort and Patient Survey were observed in pulmonary tuberculosis and nephrotic syndrome.

Basic characteristics (Lifestyle and physical status) {#sec3.2}
-----------------------------------------------------

We also evaluated life style including smoking and alcohol intake history, and physical status including BMI and blood pressure, at enrollment in the BBJ cohort. We included participants ≥20 years of age in this analysis because the frequency of smoking, alcohol intake, and hypertension among individuals under 20 years of age is quite low, and the criteria for underweight or obesity according to BMI in children and teenagers are different from those applied to adults.[@bib8] Furthermore, we compared the BBJ cohort and the National Health and Nutrition Survey 2006 for physical and life style, after adjusting for sex and age, because sex- and age-distribution varied among diseases.

Smoking history at enrollment (including subjects both with and without information on current smoking status) was positive in 74.98% of male subjects and 21.24% of female subjects in the BBJ cohort, while current smokers accounted for 27.78% of male subjects and 10.45% of female subjects ([Table 2](#tbl2){ref-type="table"}). The highest frequency of positive smoking history in both sexes was observed in COPD, followed by PAD in male subjects, and esophageal cancer in female subjects ([Table 2](#tbl2){ref-type="table"}). The highest proportion of ex-smokers for both sexes was observed in participants with lung cancer, esophageal cancer and COPD (71.45%, 64.88% and 64.68% in male subjects, and 21.75%, 30.86% and 39.44% in female subjects, respectively), while the highest proportion of current smokers for both sexes was observed in participants with Graves\' disease (49.84% in male subjects and 24.92% in female subjects) ([Table 2](#tbl2){ref-type="table"}). We then compared age-adjusted smoking history among the 47 diseases. The frequency of smokers was highest among participants with COPD, esophageal cancer, interstitial lung diseases/pulmonary fibrosis, pancreatic cancer, and cardiovascular diseases, in which smoking was shown to be a critical risk factor ([Fig. 1](#fig1){ref-type="fig"} and [eTable 4](#appsec2){ref-type="sec"}).

A positive alcohol history at enrollment (including those with and without current drinking status) was found in 69.68% of male subjects and 28.20% of female subjects ([Table 3](#tbl3){ref-type="table"}). The proportion of current drinkers in the whole cohort was much higher than that of ex-drinkers in both sexes: 52.24% and 13.35% of male subjects and 21.70% and 3.99% of female subjects were current and ex-drinkers, respectively. Among the 47 diseases, the proportion of ex-drinkers was relatively high among participants with liver cirrhosis (34.05% in male subjects and 10.80% in female subjects), liver cancer (34.83% and 10.94%), pulmonary tuberculosis (33.17% and 11.20%), esophageal cancer (25.59% and 16%), and pancreatic cancer (29.72% and 10.14%) ([Table 3](#tbl3){ref-type="table"}). Age-adjusted alcohol intake history showed that the frequency of drinkers in esophageal cancer was remarkably higher than that in other diseases for male and female subjects ([Fig. 2](#fig2){ref-type="fig"} and [eTable 5](#appsec2){ref-type="sec"}). To highlight the smoking and drinking status in the BBJ cohort, the frequency of smokers or drinkers, stratified by sex and age group, was compared between the BBJ and the National Health and Nutrition Survey. The BBJ cohort had a higher frequency of smokers among female subjects across all age groups and among elderly male subjects, particularly among those \>60 years of age; the frequency of drinkers was almost equivalent between the BBJ and the National Health and Nutrition Survey for both sexes and across all age groups ([eFig. 2A and B and eTables 6 and 7](#appsec2){ref-type="sec"}).

Mean BMI at enrollment in the BBJ cohort was 23.51 in male subjects and 22.94 in female subjects. Analysis of BMI in each disease revealed that underweight participants (BMI\<18.5) had an increased association of various cancers, while overweight or obese participants (BMI ≥ 25) had an increased association of metabolic and cardiovascular diseases ([Table 4](#tbl4){ref-type="table"}, [Fig. 3](#fig3){ref-type="fig"} and [eTable 8](#appsec2){ref-type="sec"}). When comparing the National Health and Nutrition Survey and the BBJ, there was a greater proportion of participants with overweight or obesity in the BBJ, among male and female subjects and across all age-groups; conversely, similar distribution patterns were found when comparing the BBJ cohort and the Survey, by sex and age-group ([eFig. 2C and eTables 6 and 7](#appsec2){ref-type="sec"}). In contrast, in the BBJ cohort, there were fewer underweight participants in their twenties (for both sexes) but more underweight participants \>60 years (among male subjects) and \>50 years (among female subjects) ([eFig. 2D and eTables 6 and 7](#appsec2){ref-type="sec"}).

Nearly half of the participants of the BBJ cohort had hypertension (51.52% of male subjects and 41.11% of female subjects, [Table 4](#tbl4){ref-type="table"}) at enrollment. The frequency of hypertension in cardiovascular diseases, particularly in coronary diseases, was higher than that in other diseases, while the frequency of hypertension among cancer participants tended to be low ([Table 4](#tbl4){ref-type="table"}, [Fig. 4](#fig4){ref-type="fig"} and [eTable 9](#appsec2){ref-type="sec"}). The frequency of hypertension increased with age, similarly to the increase observed in the Survey. However, the frequency of hypertension among subjects \<50 years of age was higher and subjects \>60 years of age was lower in the BBJ cohort than in the Survey ([eFig. 2E and eTables 6 and 7](#appsec2){ref-type="sec"}).

Family history {#sec3.3}
--------------

Finally, we performed multivariate logistic-regression analysis using age and sex status as covariates to assess the association between positive family history and disease risk. We were able to obtain the questionnaire-based information regarding family history of 45 diseases out of the 47 diseases ([eTable 10](#appsec2){ref-type="sec"}). For all the diseases, except for PAD, there was a significant association with a positive family history, with an odds ratio of \>1.7 ([Fig. 5](#fig5){ref-type="fig"} and [eTable 11](#appsec2){ref-type="sec"}). Notably, the odds ratios for keloid, chronic hepatitis B, and Grave\'s disease were relatively high (149.417, 53.474, and 23.751, respectively) indicating the strong impact of genetic and familial factors on disease onset.

Discussion {#sec4}
==========

We analyzed common clinical variables at enrollment, across the whole BBJ cohort, as well as for each target disease, and we compared these results with those of the Japanese database to highlight the characteristics of the BBJ cohort. Statistical analyses were not conducted in this study, as the large-scale cohort sample in the BBJ would yield relatively low-p-values, even when absolute differences were very small. The distribution of age, life style, and physical status, showed that the characteristics of each disease group could generally be explained.

It is an established fact that smoking and/or alcohol intake are risk factors for various diseases including cancer, cardiovascular disease, hepatic disease, and respiratory disease.[@bib9], [@bib10] In fact, these diseases showed a higher frequency of participants with a positive smoking or drinking history at enrollment in the BBJ cohort ([Fig. 1](#fig1){ref-type="fig"}, [Fig. 2](#fig2){ref-type="fig"} and [eTables 4 and 5](#appsec2){ref-type="sec"}). Although we cannot estimate the odds ratios of smoking and drinking status due to the lack of control data in the present cohort, age-adjusted distributions of the smoking and drinking histories of participants suggest that these lifestyle factors have a significant impact on disease onset.

Analysis of BMI at enrollment indicated that lower BMI was more prevalent among participants with malignant tumors, while higher BMI was common among participants with metabolic and cardiovascular disease ([Fig. 3](#fig3){ref-type="fig"} and [eTable 8](#appsec2){ref-type="sec"}). Obesity could be a risk factor for dyslipidemia, type 2 diabetes, coronary disease,[@bib11] while cancer can induce weight loss. Therefore, we need to be cautious in the interpretation of the association between diseases and lifestyle or physical factors.

To highlight the characteristics of the BBJ cohort, we compared the age and sex distributions of the BBJ cohort with those of the Patient Survey for each disease, and the distributions of smoking and drinking history, BMI and hypertension in the BBJ cohort with those of the National Health and Nutrition Survey. It is difficult to discuss the discrepancy or consistency between the BBJ cohort and the Japanese database, because backgrounds of the subjects and methods to determine the numbers of patients or the distributions of life style and physical status were different. However, the comparisons between the BBJ cohort and the Japanese database gave us better insight about the characteristics of the BBJ cohort, contributing to utmost utilization of the biobank samples.

As one of our main aims was to identify genetic factors causing susceptibility to diseases, we analyzed the association between positive family history and disease onset to evaluate the impact of host genetic factors. It has been reported that a positive family history is an important risk factors for many common chronic diseases,[@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19] and keloid, chronic hepatitis B, and Graves\' disease showed the highest odds ratios for a positive family history ([Fig. 5](#fig5){ref-type="fig"}). While it is important to consider the possibility that perinatal transmission, a major route of hepatitis B virus transmission,[@bib20] resulted in the high odds ratio observed in chronic hepatitis B, several genome-wide association studies (GWAS), which identified some single nucleotide polymorphism loci significantly associated with these diseases in Japan,[@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32] support the finding that genetic factors are associated with these diseases. However, the odds ratios, calculated in the previous genomic studies, were not as high as in the present analysis, suggesting the possibility that further genomic analysis could identify novel genomic loci. In addition, the fact that common clinical variables were consistently identified across the 47 diseases enabled us to evaluate and compare the risk significance of the positive family history on the diseases and to perform further genomic or other "omics" analyses based on these results.

This study has some limitations. We could not eliminate the possibility of reporting bias, causing significantly higher odds ratio of positive family history in almost all target diseases, as the information on family history was mainly based on participants\' interviews, although this was completed by certified medical coordinators. Another limitation of this analysis is that the reference population for each logistic analysis was not the disease-free general population but the participants with the other diseases in the cohort. Therefore, again, we need to take into account selection bias.[@bib33]

In conclusion, we have established a large biobank cohort, consisting of approximately 200,000 patients with 47 diseases. Analysis of the clinical dataset and comparisons between the present cohort and the Japanese database largely revealed consistent trends in common clinical variables, particularly among participants aged ≥40 years, suggesting that the sampling is representative for the general patient population in Japan. Further analysis, combined with various high-throughput 'omics' technologies, using their DNA and serum samples, will aid us to identify novel genomic variants or biomarkers associated with disease progression or drug efficacy, contributing to the implementation of personalized medicine.
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![**Age-adjusted ratios of participants with a smoking history for each disease.** The distributions of male (**A**) and female (**B**) participants with a smoking history in the BBJ cohort and in the National Health and Nutrition Survey (Japan, 2006) were compared. Age-adjustment was performed according to the age distribution of the National Health and Nutrition Survey (Japan, 2006).](gr1){#fig1}

![**Age-adjusted ratio of participants with alcohol history in each disease.** The distributions of male (**A**) and female (**B**) participants with a drinking history in the BBJ cohort and in the National Health and Nutrition Survey (Japan, 2006) were compared. Age-adjustment was performed according to the age distribution of the National Health and Nutrition Survey (Japan, 2006).](gr2){#fig2}

![**Age-adjusted ratio of participants with overweight or underweight in each disease.** The distributions of obese or underweight participants among male (**A**) and female (**B**) subjects in the BBJ cohort and in the National Health and Nutrition Survey (Japan, 2006) were compared. Age-adjustment was performed according to the age distribution of the National Health and Nutrition Survey (Japan, 2006). BMI ≥25 was defined as overweight and BMI less than 18.5 was defined as underweight.](gr3){#fig3}

![**Age-adjusted ratio of participants with hypertension in each disease.** The distributions of male (**A**) and female (**B**) participants with hypertension in the BBJ cohort and in the National Health and Nutrition Survey (Japan, 2006) were compared. Age-adjustment was performed according to the age distribution of the National Health and Nutrition Survey (Japan, 2006). Participants with a systolic blood pressure ≥135-mmHg, a diastolic blood pressure ≥90-mmHg, or participants prescribed antihypertensive medication, were diagnosed with hypertension.](gr4){#fig4}

![**Sex- and age-adjusted odds ratios in family history, related with the 47 diseases.** Dots represent odds ratios and bars represent 95% CIs by logistic regression analysis. The list of family histories, associated with the 47 diseases, is set out in [eTable 2](#appsec2){ref-type="sec"}.](gr5){#fig5}

###### 

Baseline characteristics of participants with 47 diseases in the present cohort.

Table 1

  47 Diseases                                    Number of Subjects   Mean (SD) age at registration (y)   \% of male subjects   \% of male patients (Patient survey)                           
  ---------------------------------------------- -------------------- ----------------------------------- --------------------- -------------------------------------- ----------- ----------- ---------
  **Whole cohort**                               **199,982**          **62.66**                           **14.66**             **61.55**                              **16.02**   **53.05**   **N/A**
  Lung cancer                                    3779                 67.64                               9.54                  66.07                                  9.81        64.25       50.51
  Esophageal cancer                              1291                 65.66                               8.06                  65.56                                  10.44       86.29       84.00
  Gastric cancer                                 6322                 67.01                               9.90                  65.18                                  11.77       73.39       66.27
  Colorectal cancer                              6759                 67.10                               9.95                  66.42                                  10.86       62.76       55.54
  Liver cancer                                   1924                 67.37                               8.47                  69.97                                  8.15        75.68       68.18
  Pancreatic cancer                              392                  66.02                               9.80                  66.21                                  11.02       64.54       50.85
  Gallbladder/cholangiocarcinoma                 392                  67.71                               9.22                  68.75                                  9.05        62.50       51.02
  Prostate cancer                                5066                 72.60                               7.46                  N/A                                    100.00      100.00      
  Breast cancer                                  6336                 63.74                               11.21                 57.67                                  11.98       0.73        1.33
  Uterine cervical cancer                        1218                 N/A                                 51.83                 13.33                                  0.00        0.00        
  Uterine corpus cancer                          1026                 N/A                                 58.93                 10.65                                  0.00        0.00        
  Ovarian cancer                                 888                  N/A                                 56.39                 11.91                                  0.00        0.00        
  Hematological cancer                           1307                 60.99                               15.08                 60.26                                  16.65       54.32       53.97
  Cerebral infarction                            16,534               68.82                               9.90                  71.68                                  10.60       62.27       44.37
  Cerebral aneurysm                              2710                 60.52                               11.51                 62.84                                  10.78       35.24       N/A
  Epilepsy                                       2303                 46.56                               21.75                 43.31                                  21.98       57.27       54.42
  Bronchial asthma                               8700                 51.89                               23.11                 53.54                                  20.68       49.32       51.51
  Pulmonary tuberculosis                         863                  62.14                               16.82                 62.43                                  19.34       71.38       64.10
  Chronic obstructive pulmonary disease          2774                 72.33                               8.57                  72.71                                  9.82        86.81       68.28
  Interstitial lung disease/pulmonary fibrosis   808                  68.74                               11.41                 68.11                                  11.97       58.04       55.32
  Myocardial infarction                          13,272               65.92                               10.37                 71.19                                  9.90        80.98       64.32
  Unstable angina                                4330                 66.76                               9.71                  71.26                                  9.15        73.70       55.20
  Stable angina                                  14,807               67.86                               9.81                  71.05                                  9.71        69.39       55.20
  Arrhythmia                                     15,912               67.03                               11.67                 69.27                                  12.52       64.38       52.24
  Heart failure                                  7610                 66.01                               12.63                 71.46                                  12.72       61.81       38.18
  Peripheral arterial diseases                   2683                 70.84                               9.02                  71.70                                  9.97        78.12       61.97
  Chronic hepatitis B                            1346                 54.57                               13.21                 55.62                                  14.97       62.63       62.50
  Chronic hepatitis C                            5819                 63.37                               11.84                 64.64                                  11.92       53.70       52.92
  Liver cirrhosis                                2519                 62.74                               11.50                 65.38                                  14.17       62.29       49.52
  Nephrotic syndrome                             1056                 47.45                               22.88                 48.23                                  21.74       60.32       58.06
  Urolithiasis                                   6307                 53.02                               13.72                 56.90                                  14.42       75.60       67.42
  Osteoporosis                                   6743                 72.28                               12.89                 73.77                                  9.57        7.59        7.23
  Diabetes mellitus                              39,697               63.31                               11.33                 65.80                                  12.00       63.23       52.74
  Dyslipidemia                                   43,812               62.15                               11.97                 66.26                                  10.79       50.76       33.55
  Graves\' disease                               2323                 49.86                               14.23                 49.04                                  15.75       27.85       22.22
  Rheumatoid arthritis                           4139                 64.05                               12.12                 62.39                                  12.29       20.25       18.87
  Hay fever                                      5658                 46.39                               17.63                 44.94                                  15.84       42.93       46.74
  Drug eruption                                  585                  60.53                               16.17                 54.82                                  17.46       45.81       N/A
  Atopic dermatitis                              2938                 29.98                               14.85                 29.74                                  13.54       53.13       51.61
  Keloid                                         809                  48.53                               19.97                 43.31                                  19.60       38.94       N/A
  Uterine fibroid                                5904                 N/A                                 44.69                 9.49                                   0.00        0.00        
  Endometriosis                                  1843                 N/A                                 38.93                 8.22                                   0.00        0.00        
  Febrile seizure                                333                  4.16                                3.57                  4.35                                   5.09        60.96       N/A
  Glaucoma                                       4755                 66.87                               12.43                 70.03                                  10.95       46.79       41.98
  Cataract                                       20,002               70.43                               10.31                 72.91                                  9.52        44.81       36.83
  Periodontitis                                  3898                 58.20                               15.92                 56.59                                  16.00       43.69       41.03
  Amyotrophic lateral sclerosis                  782                  60.86                               10.21                 61.03                                  10.76       64.32       N/A

###### 

Baseline smoking status of participants with 47 diseases in the present cohort.

Table 2

  47 Diseases                                    Smoking status                                                                         
  ---------------------------------------------- ---------------- ----------- ----------- ---------- ----------- ---------- ----------- ----------
  **Whole cohort**                               **25.02**        **43.75**   **27.78**   **3.45**   **78.76**   **9.37**   **10.45**   **1.42**
  Lung cancer                                    11.73            71.45       14.05       2.78       73.39       21.75      3.89        0.97
  Esophageal cancer                              10.92            64.88       18.74       5.46       56.57       30.86      9.14        3.43
  Gastric cancer                                 18.53            55.01       22.72       3.74       76.16       15.33      7.36        1.15
  Colorectal cancer                              22.87            49.81       23.78       3.55       79.54       12.14      6.94        1.38
  Liver cancer                                   20.39            45.13       26.84       7.64       77.29       10.48      9.17        3.06
  Pancreatic cancer                              15.60            55.60       28.00       0.80       66.91       16.55      14.39       2.16
  Gallbladder/cholangiocarcinoma                 26.34            48.15       21.40       4.12       80.69       10.34      6.90        2.07
  Prostate cancer                                31.88            46.54       17.19       4.39       N/A                                
  Breast cancer                                  42.22            42.22       15.56       0.00       78.24       13.04      7.63        1.08
  Uterine cervical cancer                        N/A              63.60       14.36       19.09      2.96                               
  Uterine corpus cancer                          N/A              80.80       9.35        8.16       1.69                               
  Ovarian cancer                                 N/A              80.09       9.55        8.85       1.51                               
  Hematologic cancer                             27.99            45.60       20.20       6.20       81.41       10.15      6.02        2.41
  Cerebral infarction                            24.86            47.69       24.36       3.10       82.97       8.96       6.77        1.30
  Cerebral aneurysm                              19.06            48.99       27.80       4.15       69.68       15.69      12.59       2.04
  Epilepsy                                       36.12            28.21       31.45       4.22       76.19       7.52       14.79       1.50
  Bronchial asthma                               26.44            40.08       30.96       2.53       65.90       13.48      19.24       1.39
  Pulmonary tuberculosis                         19.31            50.17       29.04       1.49       78.84       10.79      8.30        2.07
  Chronic obstructive pulmonary disease          7.31             64.68       25.81       2.20       35.77       39.44      22.54       2.25
  Interstitial lung disease/pulmonary fibrosis   13.07            62.96       20.04       3.92       72.59       18.07      8.73        0.60
  Myocardial infarction                          17.96            56.98       21.56       3.50       70.36       17.62      10.56       1.45
  Unstable angina                                21.60            55.61       20.26       2.52       76.59       13.85      8.58        0.98
  Stable angina                                  21.70            54.36       21.95       1.99       79.56       11.64      8.07        0.74
  Arrhythmia                                     25.61            50.01       21.42       2.95       83.20       9.58       6.50        0.72
  Heart failure                                  23.68            49.63       23.05       3.63       79.32       12.06      7.53        1.09
  Peripheral arterial disease                    10.39            52.66       31.74       5.22       64.67       20.91      12.65       1.76
  Chronic hepatitis B                            28.69            31.11       34.87       5.33       77.30       8.79       12.47       1.43
  Chronic hepatitis C                            22.32            38.40       34.49       4.79       74.75       9.21       13.71       2.33
  Liver cirrhosis                                19.74            34.05       40.65       5.56       73.94       10.80      13.25       2.00
  Nephrotic syndrome                             26.97            39.89       30.52       2.62       69.25       14.40      12.74       3.60
  Urolithiasis                                   29.17            28.68       38.46       3.69       76.98       5.49       15.61       1.92
  Osteoporosis                                   32.60            38.83       25.15       3.42       87.79       5.27       5.99        0.95
  Diabetes mellitus                              23.08            41.24       32.45       3.24       78.49       9.26       11.11       1.15
  Dyslipidemia                                   24.42            43.83       27.52       4.23       81.61       8.26       8.80        1.33
  Graves\' disease                               20.20            26.06       49.84       3.91       60.68       12.90      24.92       1.50
  Rheumatoid arthritis                           17.30            41.84       35.46       5.40       78.09       8.53       11.41       1.97
  Hay fever                                      42.40            28.30       24.43       4.88       77.01       8.91       12.18       1.89
  Drug eruption                                  25.00            42.58       29.69       2.73       72.37       9.54       16.45       1.64
  Atopic dermatitis                              48.12            13.75       36.53       1.60       70.64       7.06       20.91       1.39
  Keloid                                         38.08            35.43       25.17       1.32       72.69       7.96       18.06       1.29
  Uterine fibroid                                N/A              73.66       9.34        14.68      2.31                               
  Endometriosis                                  N/A              70.96       8.86        16.67      3.52                               
  Febrile seizure                                100.00           0.00        0.00        0.00       100.00      0.00       0.00        0.00
  Glaucoma                                       30.31            42.49       24.10       3.10       87.76       5.98       4.87        1.39
  Cataract                                       28.69            43.61       24.22       3.47       86.66       6.23       5.95        1.17
  Periodontitis                                  35.55            27.76       36.06       0.63       78.78       6.10       14.63       0.49
  Amyotrophic lateral sclerosis                  37.10            17.97       41.94       3.00       84.67       2.30       13.03       0.00

###### 

Baseline alcohol intake status of participants with 47 diseases in the present cohort.

Table 3

  47 Diseases                             Alcohol intake                                                                         
  --------------------------------------- ---------------- ----------- ----------- ---------- ----------- ---------- ----------- ----------
  **Whole cohort**                        **30.32**        **13.35**   **52.24**   **4.09**   **71.80**   **3.99**   **21.70**   **2.52**
  Lung cancer                             26.73            15.85       54.21       3.21       69.94       6.37       21.81       1.87
  Esophageal cancer                       8.29             25.59       61.38       4.74       47.43       16.00      32.00       4.57
  Gastric cancer                          25.19            18.96       51.49       4.36       73.12       7.57       17.62       1.69
  Colorectal cancer                       23.53            15.88       56.15       4.45       73.11       5.83       18.99       2.08
  Liver cancer                            23.90            34.83       33.01       8.27       76.59       10.94      9.41        3.06
  Pancreatic cancer                       25.70            29.72       42.97       1.61       65.22       10.14      23.91       0.72
  Gallbladder/cholangiocarcinoma          30.58            27.27       38.43       3.72       84.83       2.07       13.10       0.00
  Prostate cancer                         29.33            13.05       51.47       6.16       N/A                                
  Breast cancer                           28.89            11.11       60.00       0.00       63.67       5.21       29.02       2.10
  Uterine cervical cancer                 N/A              58.90       5.57        30.80      4.73                               
  Uterine corpus cancer                   N/A              71.02       3.59        22.51      2.89                               
  Ovarian cancer                          N/A              68.91       3.83        24.13      3.13                               
  Hematologic cancer                      29.05            12.28       50.72       7.95       72.76       5.69       18.10       3.45
  Cerebral infarction                     28.51            18.33       49.38       3.78       79.64       4.97       13.67       1.73
  Cerebral aneurysm                       23.72            15.81       55.34       5.13       66.86       6.69       24.05       2.40
  Epilepsy                                37.35            16.11       42.03       4.50       66.54       4.67       25.88       2.90
  Bronchial asthma                        34.16            9.44        53.53       2.87       69.26       3.83       25.29       1.62
  Pulmonary tuberculosis                  30.69            33.17       34.32       1.82       74.69       11.20      12.03       2.07
  Chronic obstructive pulmonary disease   38.48            17.86       42.01       1.66       74.50       6.80       17.00       1.70
  Interstitial lung disease               32.02            17.32       46.71       3.95       76.74       4.53       16.62       2.11
  Myocardial infarction                   41.68            13.70       41.29       3.32       79.48       5.42       13.48       1.62
  Unstable angina                         39.27            13.59       44.10       3.04       78.80       4.56       14.76       1.88
  Stable angina                           34.04            13.74       49.55       2.67       78.71       4.68       15.27       1.35
  Arrhythmia                              26.37            14.17       56.05       3.42       75.69       4.33       18.60       1.37
  Heart failure                           32.31            17.08       46.34       4.27       79.82       5.78       13.30       1.09
  PAD                                     31.01            19.94       43.80       5.24       77.46       8.10       11.62       2.82
  Chronic hepatitis B                     27.18            18.08       47.45       7.28       68.43       5.70       24.03       1.83
  Chronic hepatitis C                     30.61            26.60       37.50       5.29       72.35       8.90       15.51       3.25
  Liver cirrhosis                         19.23            35.20       38.92       6.65       70.86       11.35      14.24       3.56
  Nephrotic syndrome                      39.70            14.42       41.95       3.93       67.59       6.37       23.82       2.22
  Urolithiasis                            32.49            5.44        56.80       5.27       72.96       2.72       22.00       2.32
  Osteoporosis                            39.63            14.43       42.89       3.05       82.07       2.47       13.70       1.76
  Diabetes mellitus                       31.47            15.17       49.88       3.49       79.10       5.29       14.02       1.59
  Dyslipidemia                            30.78            10.71       54.08       4.44       76.03       3.40       18.52       2.06
  Graves\' disease                        38.24            8.82        48.37       4.58       66.73       5.02       25.93       2.32
  Rheumatoid arthritis                    35.47            13.79       44.95       5.79       75.46       4.11       17.89       2.54
  Hay fever                               31.18            4.31        58.22       6.29       59.31       2.80       32.50       5.40
  Drug eruption                           30.98            15.29       49.02       4.71       71.57       2.68       21.74       4.01
  Atopic dermatitis                       45.44            3.68        47.04       3.84       57.37       2.44       36.62       3.57
  Keloid                                  39.33            7.33        50.67       2.67       63.71       1.51       33.69       1.08
  Uterine fibroid                         N/A              53.52       2.23        38.57      5.67                               
  Endometriosis                           N/A              55.51       2.26        34.56      7.66                               
  Febrile seizure                         100.00           0.00        0.00        0.00       66.67       0.00       33.33       0.00
  Glaucoma                                27.42            12.46       56.14       3.98       77.61       2.98       17.16       2.25
  Cataract                                31.05            14.42       50.58       3.95       81.00       2.95       14.49       1.57
  Periodontitis                           29.82            7.20        61.53       1.45       63.54       2.75       32.14       1.57
  Amyotrophic lateral sclerosis           28.57            0.00        57.14       14.29      100.00      0.00       0.00        0.00

###### 

Baseline BMI and hypertension of participants with 47 diseases in the present cohort.

Table 4

  47 Diseases                                    BMI         %Hypertension                                      
  ---------------------------------------------- ----------- --------------- ----------- ---------- ----------- -----------
  **Whole cohort**                               **23.51**   **3.47**        **22.94**   **3.89**   **51.52**   **41.11**
  Lung cancer                                    22.29       3.05            22.05       3.37       36.74       33.83
  Esophageal cancer                              20.53       2.96            19.77       3.25       27.29       24.86
  Gastric cancer                                 21.25       3.04            20.34       3.26       30.91       24.26
  Colorectal cancer                              22.66       3.17            22.00       3.51       38.00       30.31
  Liver cancer                                   22.68       3.27            22.82       3.96       44.64       45.51
  Pancreatic cancer                              20.44       3.19            19.90       3.03       30.83       29.50
  Gallbladder/cholangiocarcinoma                 21.46       3.29            22.20       3.89       33.47       31.29
  Prostate cancer                                23.28       2.86            N/A         38.00      N/A         
  Breast cancer                                  23.87       3.75            22.74       3.60       52.17       22.82
  Cervical cancer                                N/A         21.93           3.29        N/A        19.23       
  Uterine cancer                                 N/A         23.74           4.37        N/A        25.83       
  Ovarian cancer                                 N/A         22.04           3.38        N/A        19.21       
  Hematopoietic tumor                            23.11       3.23            21.87       3.33       30.94       26.71
  Cerebral infarction                            23.53       3.19            23.39       3.86       67.12       65.34
  Cerebral aneurysm                              23.86       3.36            23.11       3.64       65.45       59.52
  Epilepsy                                       23.47       3.84            22.70       4.19       36.36       25.64
  Bronchial asthma                               23.79       3.71            23.78       4.55       41.19       35.14
  Pulmonary tuberculosis                         20.82       3.28            20.26       3.26       32.31       37.80
  Chronic obstructive pulmonary disease          21.30       3.37            20.33       4.08       46.05       44.66
  Interstitial lung disease/pulmonary fibrosis   23.02       3.21            22.62       3.75       42.37       40.65
  Myocardial infarction                          24.04       3.23            23.40       3.74       73.11       77.01
  Unstable angina                                24.02       3.21            23.74       3.74       74.33       74.80
  Stable angina                                  23.85       3.16            23.63       3.66       77.17       77.45
  Arrhythmia                                     23.53       3.30            22.90       3.80       66.75       65.33
  Heart failure                                  23.50       3.89            22.64       4.31       78.70       78.10
  Peripheral arterial diseases                   22.52       3.25            22.44       3.80       70.21       69.17
  Chronic hepatitis B                            23.32       3.11            22.55       3.51       40.67       33.60
  Chronic hepatitis C                            22.86       3.15            22.54       3.65       46.19       40.71
  Liver cirrhosis                                22.88       3.51            23.03       4.05       52.18       49.41
  Nephrotic syndrome                             23.00       3.34            22.50       3.94       62.32       50.68
  Urolithiasis                                   24.43       3.39            23.59       4.16       37.27       35.61
  Osteoporosis                                   21.96       3.52            22.26       3.62       49.22       44.46
  Diabetes mellitus                              24.03       3.72            24.57       4.41       60.32       62.82
  Dyslipidemia                                   24.78       3.45            24.11       3.88       64.47       59.48
  Graves\' disease                               23.55       3.63            22.35       3.61       41.03       32.00
  Rheumatoid arthritis                           22.49       3.29            21.85       3.69       40.57       33.56
  Hay fever                                      23.66       3.17            22.06       3.51       24.70       14.77
  Drug eruption                                  23.27       3.39            22.62       4.07       49.81       30.87
  Atopic dermatitis                              23.01       3.51            21.48       3.70       13.24       5.75
  Keloid                                         23.95       3.29            22.71       4.11       27.60       18.82
  Uterine fibroid                                N/A         22.29           3.51        N/A        14.09       
  Endometriosis                                  N/A         21.43           3.25        N/A        7.93        
  Febrile seizure                                28.73       0.00            21.26       4.80       N/A         N/A
  Glaucoma                                       23.05       3.18            22.90       3.66       43.87       41.08
  Cataract                                       23.08       3.15            23.05       3.85       49.53       45.68
  Periodontitis                                  23.27       3.14            22.25       3.37       27.33       15.90
  Amyotrophic lateral sclerosis                  21.14       1.68            28.00       3.14       N/A         N/A

[^1]: Hospital Group members are listed in [Appendix A](#appsec1){ref-type="sec"}.
